Loading...
Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment
In recent years, targeted therapy and immunotherapy have played important roles in the treatment of patients with non-small-cell lung cancer (NSCLC). Drugs that target epidermal growth factor receptor (EGFR) mutations (eg, gefitinib, erlotinib, icotinib, and osimertinib) are among the most commonly...
Na minha lista:
| Udgivet i: | Onco Targets Ther |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6163004/ https://ncbi.nlm.nih.gov/pubmed/30288054 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S178497 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|